Pharmaceutical

GS-4528 by Gilead Sciences for Metastatic Renal Cell Carcinoma: Likelihood of Approval

GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Metastatic Renal Cell Carcinoma.

Dec 26, 2023 - 18:00
GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Metastatic Renal Cell Carcinoma.
Read the original article

Tags:

Previous Article

NT-175 by Neogene Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC):...

Next Article

ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HN...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma

Innate shelves lacutamab monotherapy plans in periphera...

Mar 24, 2024

BW-20507 by Argo Biopharma Australia for Hepatitis B: L...

Oct 3, 2023

Magazine: UK’s new Netflix-style funding model for antibiotics goes live

Magazine: UK’s new Netflix-style funding model for anti...

Jun 26, 2024